Drugs / Prenisolone
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06097364 Background | Nov 2023 → Jul 2029 expected | follicular lymphoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prenisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097364 ↗ |
| Route | Oral | “Administered orally (PO)” NCT06097364 ↗ |